FDA Reviewing Cancer Trial Endpoints, Oncology Director Pazdur Tells ASCO
Executive Summary
FDA's Division of Oncologic Drug Products will conduct an internal review of regulatory endpoints for cancer trials, division Director Richard Pazdur, MD, said May 13 during the American Society of Clinical Oncology annual meeting in San Francisco.